Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2023-12-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于2023年第二期限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to a restricted stock incentive plan for the year 2023. It details the scope, procedures, and findings of the investigation into whether insiders traded company stock during the relevant period. The document is a regulatory announcement about compliance and insider trading checks, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is also not a report publication announcement since it contains substantive content about the investigation results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-18 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2023年第五次临时股东大会的法律意见书
Regulatory Filings
2023-12-18 Chinese
圣湘生物科技股份有限公司2023年第五次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the company's 2023 fifth extraordinary general meeting of shareholders, including voting results, meeting attendance, and legal witness statements. It contains no financial statements or management discussion but focuses on shareholder meeting outcomes and voting details. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2643 characters, which is consistent with a detailed voting results announcement rather than a brief report publication or a full annual/interim report.
2023-12-18 Chinese
圣湘生物科技股份有限公司监事会关于公司2023年第二期限制性股票激励计划首次授予激励对象名单的审核意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is an official announcement from the supervisory board regarding the review and public disclosure of the first grant list of incentive recipients under the company's 2023 second restricted stock incentive plan. It details the internal review process, compliance with relevant laws and regulations, and the public notice period. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement related to stock incentive plans and compliance verification. Given the content and length (1768 characters), it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-12 Chinese
圣湘生物科技股份有限公司2023年第五次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2023 Fifth Extraordinary General Meeting (EGM) Meeting Materials" of 圣湘生物科技股份有限公司. It contains detailed meeting instructions, agenda, and proposals for shareholder approval, including stock incentive plans and authorizations for the board. The content is clearly related to materials prepared for a specific shareholders' meeting rather than a report or announcement of results. The document length is 6637 characters, which is consistent with detailed meeting materials. There is no financial statement or earnings data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a voting results announcement since it is the meeting materials, not the results. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings, including extraordinary meetings.
2023-12-08 Chinese
圣湘生物科技股份有限公司2023年季度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of quarterly equity distribution (dividend) for the year 2023 by 圣湘生物科技股份有限公司. It details the dividend amount per share, relevant dates (record date, ex-dividend date, payment date), the approval by the shareholders' meeting, tax treatment, and distribution methods. The document does not contain financial statements or comprehensive financial performance data but focuses on dividend distribution specifics. It is not a full annual or quarterly report, nor a management discussion or earnings release. The document is a formal announcement of dividend amount and payment details, fitting the category of Notice of Dividend Amount (DIV). The document length is under 5,000 characters and is a detailed dividend announcement, not a report publication announcement or regulatory filing.
2023-12-04 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.